

Richard A Burkhart

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3170333/publications.pdf>

Version: 2024-02-01

85
papers

3,066
citations

218677

26
h-index

182427

51
g-index

86
all docs

86
docs citations

86
times ranked

4580
citing authors

#	ARTICLE	IF	CITATIONS
1	Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. <i>Cell</i> , 2017, 170, 875-888.e20.	28.9	339
2	Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. <i>Annals of Surgery</i> , 2019, 270, 340-347.	4.2	280
3	Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2019, 269, 1154-1162.	4.2	222
4	Association of <i>BRAF</i> Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. <i>JAMA Surgery</i> , 2018, 153, e180996.	4.3	151
5	Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. <i>Nature Cancer</i> , 2021, 2, 891-903.	13.2	147
6	Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?. <i>Annals of Surgery</i> , 2018, 268, 1-8.	4.2	139
7	Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status. <i>Annals of Surgery</i> , 2018, 268, 408-420.	4.2	125
8	Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4973-4984.	7.0	118
9	Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes. <i>Cancer Discovery</i> , 2020, 10, 1566-1589.	9.4	90
10	Negative Pressure Wound Therapy for Surgical-site Infections. <i>Annals of Surgery</i> , 2019, 269, 1034-1040.	4.2	86
11	Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 2475-2483.	1.5	77
12	Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1674-1683.	1.0	62
13	Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. <i>Annals of Surgery</i> , 2020, 272, 427-435.	4.2	61
14	Main Duct Dilatation Is the Best Predictor of High-grade Dysplasia or Invasion in Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Annals of Surgery</i> , 2020, 272, 1118-1124.	4.2	58
15	Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome. <i>Cancer Research</i> , 2020, 80, 2804-2817.	0.9	58
16	Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5351-5363.	7.0	57
17	Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 112-121.	1.7	54
18	Implications of Perineural Invasion on Disease Recurrence and Survival After Pancreatectomy for Pancreatic Head Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 276, 378-385.	4.2	50

#	ARTICLE	IF	CITATIONS
19	Personalized therapy in hepatocellular carcinoma: Molecular markers of prognosis and therapeutic response. <i>Surgical Oncology</i> , 2017, 26, 138-145.	1.6	49
20	Perioperative Outcomes of Robotic Pancreaticoduodenectomy: a Propensity-Matched Analysis to Open and Laparoscopic Pancreaticoduodenectomy. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1795-1804.	1.7	43
21	Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy. <i>Journal of the American College of Surgeons</i> , 2021, 232, 405-413.	0.5	39
22	Enhancing Patient Outcomes while Containing Costs after Complex Abdominal Operation: A Randomized Controlled Trial of the Whipple Accelerated Recovery Pathway. <i>Journal of the American College of Surgeons</i> , 2019, 228, 415-424.	0.5	38
23	Periadventitial dissection of the superior mesenteric artery for locally advanced pancreatic cancer: Surgical planning with the "œhalo sign" and "œstring sign". <i>Surgery</i> , 2021, 169, 1026-1031.	1.9	37
24	The use of negative pressure wound therapy to prevent post-operative surgical site infections following pancreaticoduodenectomy. <i>Hpb</i> , 2017, 19, 825-831.	0.3	35
25	Preoperative risk factors for conversion and learning curve of minimally invasive distal pancreatectomy. <i>Surgery</i> , 2017, 162, 1040-1047.	1.9	33
26	The Prognostic Impact of Primary Tumor Site Differs According to the KRAS Mutational Status. <i>Annals of Surgery</i> , 2021, 273, 1165-1172.	4.2	33
27	An Aggressive Approach to Locally Confined Pancreatic Cancer: Defining Surgical and Oncologic Outcomes Unique to Pancreatectomy with Celiac Axis Resection (DP-CAR). <i>Annals of Surgical Oncology</i> , 2021, 28, 3125-3134.	1.5	28
28	Role of exosomes in treatment of hepatocellular carcinoma. <i>Surgical Oncology</i> , 2017, 26, 219-228.	1.6	27
29	Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. <i>Annals of Surgery</i> , 2021, 274, 162-169.	4.2	25
30	Staging and Prognostic Models for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. <i>Cancer Control</i> , 2017, 24, 107327481772923.	1.8	24
31	Surgical Resection of 78 Pancreatic Solid Pseudopapillary Tumors: a 30-Year Single Institutional Experience. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 874-881.	1.7	23
32	Mesoportal bypass, interposition graft, and mesocaval shunt: Surgical strategies to overcome superior mesenteric vein involvement in pancreatic cancer. <i>Surgery</i> , 2020, 168, 1048-1055.	1.9	22
33	Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival. <i>Hpb</i> , 2019, 21, 998-1008.	0.3	21
34	Geographical variation and trends in outcomes of laparoscopic spleen-preserving distal pancreatectomy with or without splenic vessel preservation: A meta-analysis. <i>International Journal of Surgery</i> , 2017, 45, 47-55.	2.7	20
35	Disparities in the Use of Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1590-1596.	1.7	19
36	Pancreatic circulating tumor cell detection by targeted single-cell next-generation sequencing. <i>Cancer Letters</i> , 2020, 493, 245-253.	7.2	18

#	ARTICLE	IF	CITATIONS
37	Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells. <i>Cancer Biology and Medicine</i> , 2021, 18, 206-214.	3.0	18
38	Using Artificial Intelligence to Find the Optimal Margin Width in Hepatectomy for Colorectal Cancer Liver Metastases. <i>JAMA Surgery</i> , 2022, 157, e221819.	4.3	16
39	Management of Type 9 Hepatic Arterial Anatomy at the time of Pancreaticoduodenectomy: Considerations for Preservation and Reconstruction of a Completely Replaced Common Hepatic Artery. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1400-1404.	1.7	15
40	The Prognostic Value of Varying Definitions of Positive Resection Margin in Patients with Colorectal Cancer Liver Metastases. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 1350-1357.	1.7	15
41	The Impact of Clinical and Pathological Features on Intraductal Papillary Mucinous Neoplasm Recurrence After Surgical Resection. <i>Annals of Surgery</i> , 2022, 275, 1165-1174.	4.2	15
42	Lessons learned from 29 lymphoepithelial cysts of the pancreas: institutional experience and review of the literature. <i>Hpb</i> , 2018, 20, 612-620.	0.3	13
43	Psychosocial Risks are Independently Associated with Cancer Surgery Outcomes in Medically Comorbid Patients. <i>Annals of Surgical Oncology</i> , 2019, 26, 936-944.	1.5	13
44	Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer. <i>Surgical Oncology</i> , 2016, 25, 190-199.	1.6	12
45	Duodenal, ampullary, and pancreatic neuroendocrine tumors: Oncologic outcomes are driven by tumor biology and tissue of origin. <i>Journal of Surgical Oncology</i> , 2021, 123, 416-424.	1.7	12
46	Reliable Detection of Somatic Mutations for Pancreatic Cancer in Endoscopic Ultrasonography-Guided Fine Needle Aspirates with Next-Generation Sequencing: Implications from a Prospective Cohort Study. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 3149-3159.	1.7	12
47	Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity. <i>Annals of Surgical Oncology</i> , 2022, 29, 2456-2468.	1.5	12
48	Long-term survival after resection of sarcomatoid carcinoma of the pancreas: an updated experience. <i>Journal of Surgical Research</i> , 2017, 219, 238-243.	1.6	11
49	Testing Susceptibility of Patient-Derived Organoid Cultures to Therapies: Pharmacotyping. <i>Methods in Molecular Biology</i> , 2018, 1787, 253-261.	0.9	11
50	A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2019, 48, 973-984.	1.1	11
51	Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma. <i>Journal of the American College of Surgeons</i> , 2020, 231, 527-535.e14.	0.5	11
52	Evaluation of a Novel Absorbable Radiopaque Hydrogel in Patients Undergoing Image Guided Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. <i>Practical Radiation Oncology</i> , 2020, 10, e508-e513.	2.1	11
53	Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 401-414.	1.5	11
54	Defining a minimum number of examined lymph nodes improves the prognostic value of lymphadenectomy in pancreas ductal adenocarcinoma. <i>Hpb</i> , 2021, 23, 575-586.	0.3	10

#	ARTICLE	IF	CITATIONS
55	Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. <i>Cancer Letters</i> , 2021, 497, 221-228.	7.2	10
56	Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma. <i>JCI Insight</i> , 2021, 6, .	5.0	10
57	Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. <i>Oncolmmunology</i> , 2021, 10, 2001159.	4.6	10
58	The impact of high body mass index on patients undergoing robotic pancreatectomy: A propensity matched analysis. <i>Surgery</i> , 2020, 167, 556-559.	1.9	9
59	Role of Lymph Node Resection and Histopathological Evaluation in Accurate Staging of Nonfunctional Pancreatic Neuroendocrine Tumors: How Many Are Enough?. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 428-435.	1.7	8
60	Postoperative biliary anastomotic strictures after pancreaticoduodenectomy. <i>Hpb</i> , 2021, 23, 1716-1721.	0.3	8
61	Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. <i>Surgery</i> , 2022, 171, 1379-1387.	1.9	7
62	Neoadjuvant and adjuvant antitumor vaccination alone or combination with PD1 blockade and CD137 agonism in patients with resectable pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 558-558.	1.6	7
63	Minimal main pancreatic duct dilatation in small branch duct intraductal papillary mucinous neoplasms associated with high-grade dysplasia or invasive carcinoma. <i>Hpb</i> , 2021, 23, 468-474.	0.3	6
64	Incidence and Contemporary Management of Delayed Bleeding Following Pancreaticoduodenectomy. <i>World Journal of Surgery</i> , 2022, 46, 1161-1171.	1.6	6
65	Laparoscopic total pancreatectomy with islet autotransplantation for chronic pancreatitis. <i>Journal of Visualized Surgery</i> , 2016, 2, 121-121.	0.2	5
66	Laparoscopic hepatectomy for hepatocellular carcinoma: are oncologic outcomes truly superior to an open approach?. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 174-, 200-202.	1.5	5
67	Radical antegrade modular pancreatosplenectomy versus standard distal pancreatosplenectomy for pancreatic cancer, a dual-institutional analysis. <i>Chinese Clinical Oncology</i> , 2020, 9, 54-54.	1.2	5
68	A phase 2 study of cyclophosphamide (CY), GVAX, pembrolizumab (Pembro), and stereotactic body radiation (SBRT) in patients (pts) with locally advanced pancreas cancer (LAPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4134-4134.	1.6	5
69	Modeling human pancreatic ductal adenocarcinoma for translational research: current options, challenges, and prospective directions. <i>Annals of Pancreatic Cancer</i> , 2020, 3, 17-17.	1.2	5
70	Accurate Nodal Staging in Pancreatic Cancer in the Era of Neoadjuvant Therapy. <i>World Journal of Surgery</i> , 2022, 46, 667-677.	1.6	5
71	Pancreatic Nerve Sheath Tumors: a Single Institutional Series and Systematic Review of the Literature. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 841-848.	1.7	4
72	Multidisciplinary management and the future of treatment in cholangiocarcinoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 255-267.	0.8	2

#	ARTICLE	IF	CITATIONS
73	Missed psychosocial risk factors during routine preoperative evaluations are associated with increased complications after elective cancer surgery. <i>Surgery</i> , 2019, 166, 177-183.	1.9	2
74	Nontumor related risk score: A new tool to improve prediction of prognosis after hepatectomy for colorectal liver metastases. <i>Surgery</i> , 2022, 171, 1580-1587.	1.9	2
75	Surgical Site Infections Following Pancreaticoduodenectomy. <i>Hpb</i> , 2017, 19, 1131.	0.3	1
76	Role of Hepatectomy for Hepatocellular Carcinoma in the Era of Transplantation and Locoregional Therapy. <i>Digestive Disease Interventions</i> , 2017, 01, 094-104.	0.2	1
77	Long-term outcomes with neoadjuvant chemotherapy with or without stereotactic body radiation therapy in patients with borderline resectable and locally advanced pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 443-443.	1.6	1
78	Ovarian Metastasis from Pancreatic Ductal Adenocarcinoma. <i>World Journal of Surgery</i> , 2021, 45, 3157-3164.	1.6	1
79	ASO Visual Abstract: Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 714-715.	1.5	1
80	Solving for Chemotherapeutic Sensitivity: Adapting “Black Box” Methods to Study Patient-Derived Tumor Organoids. <i>Annals of Surgical Oncology</i> , 2022, 29, 4-6.	1.5	1
81	RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. <i>JCO Precision Oncology</i> , 2022, , .	3.0	1
82	Trial in progress: A randomized phase II study of pembrolizumab with or without defactinib, a focal adhesion kinase inhibitor, following chemotherapy as a neoadjuvant and adjuvant treatment for resectable pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4192-TPS4192.	1.6	1
83	Clinical and molecular features of adenosquamous pancreatic cancer (ASQ): A distinct histological subtype.. <i>Journal of Clinical Oncology</i> , 2021, 39, 426-426.	1.6	0
84	Abstract 2372: Mechanisms of microRNA-21 dysregulation in pancreatic ductal adenocarcinoma (PDAC). , 2021, , .		0
85	Abstract PO-111: A human single-cell RNA sequencing atlas of pancreatic ductal adenocarcinoma enables harmonized cell type calling and comprehensive analyses of potential intercellular signaling. , 2021, , .		0